Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 57.8% during the 2nd quarter, HoldingsChannel reports. The firm owned 25,456 shares of the biopharmaceutical company’s stock after selling 34,852 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $850,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Jefferies Financial Group Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $10,973,000. GW&K Investment Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 19.6% in the fourth quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock valued at $31,634,000 after buying an additional 225,238 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Ultragenyx Pharmaceutical by 57.6% during the fourth quarter. BNP Paribas Financial Markets now owns 903,050 shares of the biopharmaceutical company’s stock worth $20,770,000 after acquiring an additional 330,031 shares during the period. UBS Group AG grew its holdings in Ultragenyx Pharmaceutical by 22.3% during the fourth quarter. UBS Group AG now owns 668,811 shares of the biopharmaceutical company’s stock worth $15,383,000 after acquiring an additional 121,786 shares during the period. Finally, Vanguard Group Inc. raised its position in Ultragenyx Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after acquiring an additional 131,087 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 1.8%

Shares of RARE opened at $26.38 on Friday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $39.89. The firm has a market capitalization of $2.60 billion, a P/E ratio of -4.52 and a beta of 0.35. The stock’s fifty day simple moving average is $28.22 and its 200 day simple moving average is $24.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the firm earned ($1.17) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.5% on a year-over-year basis. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.08 earnings per share for the current year.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $50 price target for Ultragenyx, implying substantial upside from recent trading levels. Ultragenyx Pharmaceutical Earns Buy Rating from HC Wainwright
• Positive Sentiment: The firm sharply raised its Q3 2026 EPS forecast to $0.75 from a projected loss of $0.84 and increased Q4 2026 EPS to $0.78 from a loss of $0.35. Its FY2026 loss estimate also improved to $1.18 per share from $4.27, suggesting stronger near-term profitability expectations.
• Neutral Sentiment: Analyst price targets compiled by brokerages were reported at an average of $57.82, although the article did not identify a specific change in the broader consensus. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Negative Sentiment: HC Wainwright reduced its FY2027 EPS forecast to $4.50 from $5.61. Quarterly estimates were also cut for Q1 2027, to $0.06 from $0.27; Q2 2027, to $0.91 from $1.18; Q3 2027, to $1.25 from $1.54; and Q4 2027, to $2.27 from $2.63. These revisions signal slower expected earnings growth beyond 2026 and likely explain the cautious stock reaction.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 14,292 shares of company stock worth $351,644. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Royal Bank Of Canada raised their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Wedbush reduced their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.82.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.